Monday, 16 December 2019

Reuters Health Report: Axsome depression drug meets late-stage study goal, shares soar 56%

Reuters.com Newsletter

Axsome depression drug meets late-stage study goal, shares soar 56%

Axsome Therapeutics Inc said on Monday its drug succeeded in reducing symptoms of major depressive disorder in a late-stage trial, sending the company's share soaring 56% before the bell.

Novartis drops asthma drug fevipiprant after trial failures

Swiss drugmaker Novartis on Monday said it is jettisoning what it had hoped would be a billion-dollar-selling asthma drug, fevipiprant, from its development program after the medicine failed another set of key trials.

New autism guidelines focus in early diagnosis, treatment

CHICAGO (Reuters Health) - The American Academy of Pediatrics (AAP) on Monday issued its first new autism treatment guidelines in 12 years aimed at helping doctors identify at-risk children and getting them the care they need as early as possible.

Malaysia to work with UNICEF on polio vaccination in Sabah state

Malaysia's health authorities on Sunday said they are working with UNICEF to bring polio vaccines to the state of Sabah in Malaysian Borneo, where the country's first polio case in nearly three decades was detected last week.

Samoa extends measles state of emergency, NZ to fund Pacific vaccination campaign

The South Pacific island nation of Samoa on Saturday extended a state of emergency due to a measles outbreak which has killed 72 people, mostly infants, as New Zealand announced NZ$1 million ($640,700) to help combat measles in the Pacific.

Bristol-Myers wins $752 million in U.S. patent case against Gilead

Bristol-Myers Squibb Co on Friday said it won a $752 million jury verdict against Gilead Sciences Inc in a U.S. patent dispute relating to technology for treating cancer.

Sarepta shares surge after surprise approval of Duchenne Muscular Dystrophy drug

Shares of Sarepta Therapeutics Inc soared 31% on Friday after U.S. regulators shocked Wall Street by approving the company's treatment for a muscle-wasting disorder less than four months after rejecting the drug over safety concerns.

Social media use linked to teen disordered eating behaviors

(Reuters Health) - Adolescents who are active on social media may be more likely to exercise excessively, skip meals or develop other forms of disordered eating, a U.S. study suggests.

FDA panel votes unanimously in favor of Horizon's thyroid eye disease drug

Independent advisers to the U.S. Food and Drug Administration on Friday voted unanimously in favor of Horizon Therapeutics Plc's experimental treatment for active thyroid eye disease, taking the drug closer towards potential approval.

FDA says Amarin can market fish-oil derived therapy for reducing heart attack risk

U.S. health regulators on Friday approved expanding the heart benefit claims Amarin Corp can make in promoting its drug Vascepa to include reducing the risk of heart attacks and strokes in high-risk patients, opening a multibillion-dollar market opportunity.

Santa Anita introduces new technology to aid horses

Santa Anita Park, where 35 horses have died as the result of injuries in the past year, said on Friday it was introducing new technology for diagnosing pre-existing conditions in racehorses.

Related Videos

Introducing the all-new
Reuters News app

The new Reuters News app is here, redesigned from the ground up to fit your busy life.

Get it now on iOS